Josephat I Ogbonna1 ,
Mumuni A Momoh2,4,
Chinazom P Agbo2,
Hanifah Abdulmumin3,
Chinenye C Chukwu2,
John Alfa4,
Nafiu Aminu5,
James Oyeniyi5,
Umar S Okino6,
Franklin C Kenechukwu2,
Deghinmotei Alfred-Ugbenbo7,
Darlington C Youngson2
For correspondence:- Josephat Ogbonna Email: josephat.ogbonna@unn.edu.ng Tel:+234-8063285077
Received: 2 January 2025 Accepted: 15 February 2025 Published: 27 February 2025
Citation: Ogbonna JI, Momoh MA, Agbo CP, Abdulmumin H, Chukwu CC, Alfa J, et al. Development of double-coated microparticles for improved oral insulin delivery in diabetes management. Trop J Pharm Res 2025; 24(2):141-151 doi: 10.4314/tjpr.v24i2.2
© 2025 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To formulate double-coated insulin-loaded polymer-based microparticles (MPs) for oral delivery of insulin. Methods: Different formulations of insulin-loaded MPs were prepared using polyethylene glycol 4000 (PEG 4000) and chitosan as primary coat and Eudragit® RL 100 as secondary coating agents. Physicochemical characterization, in vitro drug release, toxicological, and in vivo studies in diabetic rats were performed, and the results of the orally administered MPs were compared with those of subcutaneously administered Humulin®. Results: The developed MPs showed good physicochemical characteristics. In vitro release studies showed that all batches of MPs exhibited sustained insulin release in 12 h with the highest insulin release achieved by MPs formulated using PEG 4000 as primary coating. In vivo, the orally administrated MPs containing 2 % chitosan achieved a reduction in blood glucose level from 100 mg/dL to 15.8 mg/dL after 10 h, compared to subcutaneously administered Humulin® which was 100 mg/dL to 20.60 mg/dL after 24 h. The MPs reduced blood urea (76.25 - 43.21 mg/dL) better than Humulin® (76.25 - 73.11 mg/dL), hence, may prevent development of insulin resistance and/or defective insulin release. Conclusion: The effects of these formulations on blood glucose were comparable to subcutaneously administered Humulin® in diabetic rats. However, there is need to optimize these polymer blends for improved effectiveness, as well as study the long-term stability of these formulations.
Archives
News Updates